相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 技术资料
- 保存条件:
Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 6 months; -20°C, 1 month.
- 库存:
货期:1-2天
- 供应商:
MedChemExpress LLC
- CAS号:
328543-09-5
- 规格:
10 mM * 1 mL/1 mg/5 mg/10 mg/50 mg
| 规格: | 10 mM * 1 mL | 产品价格: | ¥1392.0 |
|---|---|---|---|
| 规格: | 1 mg | 产品价格: | ¥575.0 |
| 规格: | 5 mg | 产品价格: | ¥1265.0 |
| 规格: | 10 mg | 产品价格: | ¥2380.0 |
| 规格: | 50 mg | 产品价格: | ¥7217.0 |
MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
AG14361
CAS No. : 328543-09-5
MCE 国际站:AG14361
产品活性:AG14361 是一种有效的 PARP-1 抑制剂,Ki 值 < 5 nM,在通透的 SW620 细胞和完整的 SW620 细胞中,抑制 PARP-1 的活性,IC50 值分别为 29 nM 和 14 nM。
研究领域:Cell Cycle/DNA Damage | Epigenetics
作用靶点:PARP
In Vitro: AG14361 is a potent PARP-1 inhibitor, with a Ki of < 5 nM, and in permeabilized SW620 and intact SW620 cells, the IC50s are 29 nM and 14 nM, respectively. AG14361 inhibits the proliferation of human cancer cells, such as A549, LoVo, and SW620 cells, with GI50s of 14 μM, 11.2 μM and 20 μM, respectively. Furthermore, AG14361 in combination with NSC 362856 markedly reduces the GI50 value of NSC 362856 in LoVo and A549 cells, but does not exert such an effect in SW620 cells. AG14361 suppresses breast cancer cells with IC50s of 17 μM and 25 μM for 92 J-wt-BRCA1 and 92 J-sh-BRCA1 cells, respectively. AG14361 induces caspase 3/7 activation and cell cycle abnormalities, and also inhibits NF-κB signaling. AG14361 (0.4 μM) enhances the growth-inhibitory and cytotoxic effects of topoisomerase I poisons, with no obvious effect on the formation and reversal of cleavable complexes, and increases the persistence of camptothecin-induced DNA single-strand breaks.
In Vivo: AG14361 (5 and 15 mg/kg, i.p.) has no toxicity and does not inhibit the growth of tumor. However, AG14361 markedly enhances NSC 362856 activity against LoVo xenografts and delays tumor growth when combined with NSC 362856. AG14361 (15 mg/kg, i.p.) treatment before irradiation dramaticly increases the sensitivity to radiation therapy of mice bearing LoVo xenografts. AG14361 (30 mg/kg) synergizes Lestaurtinib (HY-50867) activity on inhibiting breast cancer tumors in allografts.
相关产品:Bioactive Compound Library Plus | Cell Cycle/DNA Damage Compound Library | Epigenetics Compound Library | Anti-Cancer Compound Library | Anti-Aging Compound Library | Anti-Breast Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Highly Selective Inhibitors Library | Olaparib | XAV-939 | Talazoparib | Niraparib | Saruparib | Rucaparib | Veliparib | PJ34 | Chlorin e6 | Pamiparib | RBN-2397 | Fucosterol | Dehydrocorydaline | Fluzoparib | G007-LK | RBN012759 | 3-Aminobenzamide | Patritumab | Daphnetin | NVP-TNKS656 | Rucaparib monocamsylate | AZD-2461 | EB-47 dihydrochloride | Iniparib | Paris saponin VII
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
技术资料暂无技术资料 索取技术资料

















